Send to a Friend Share

Conmed (CNMD) Tops Q2 View By 2c; Reducing Guidance

July 30, 2009 7:36 AM EDT
CNMD Hot Sheet
Revenue Growth %: +5.9%

Financial Fact:
Cost of sales: 93.41M

Today's EPS Names:
TARO, BRLI, TLB, More
Conmed (Nasdaq: CNMD) reports Q2 EPS of $0.17, 2 cents better than the analyst estimate of $0.15. Revenue for the quarter was $164.6 million, versus the consensus of $163.04 million.

Reducing sales guidance by $10.0 million to $670 - $680 million versus $671.34M and the non-GAAP EPS guidance by $0.07 to $0.85 - $0.95 versus consensus of $0.94.

Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!

You May Also Be Interested In


Related Categories

Earnings, Guidance

Add Your Comment





Follow StreetInsider.com On Twitter